All In Biotech

Drug Trial Radar · NCT01688830

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

Randomised, Double-blind, Placebo-controlled Phase I Study in Healthy Male Volunteers. to Investigate Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 655075 (Part 1) and to Explore the Dose of BI 655075 Effective to Reverse Dabigatran Anticoagulant Activity (Part 2)

Last checked: Nov 20, 2026Latest source record: Jun 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 157 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

157

Actual

Start

Sep 2012

Primary completion

Nov 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI 655075 following intravenous administration of single rising doses of BI 655075 when administered alone and after administration of dabigatran.

Conditions

  • Healthy

Interventions

  • DabigatranDrug

  • BI 655075Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Drug Related Adverse Events (AE)Time frame: AEs occurring until end of follow-up (Up to 3 months after last drug administration)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 1321.1.1 Boehringer Ingelheim Investigational Site

    Antwerp, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.